Recent Zika virus outbreaks have been associated with severe outcomes, especially during pregnancy. A great deal of effort has been put toward understanding this virus, particularly the immune mechanisms responsible for rapid viral control in the majority of infections. Identifying and understanding the key mechanisms of immune control will provide the foundation for the development of effective vaccines and antiviral therapy. Here, we outline a mathematical modeling approach for analyzing the within-host dynamics of Zika virus, and we describe how these models can be used to understand key aspects of the viral life cycle and to predict antiviral efficacy.
| INTRODUC TI ON

Zika virus (ZIKV) is a flavivirus first isolated in Uganda in 1947
1 that is primarily transmitted between humans via a mosquito vector.
Recent outbreaks in Micronesia 2 and South America 3 have suggested an association between infection, which generally manifests as a mild fever, 4 and more severe outcomes such as neural 5 and fetal 6 complications, resulting in a global effort to understand this virus more fully.
A typical ZIKV infection produces relatively rapid viral dynamics, with the median time to undetectable viremia in the blood being on the order of 2 weeks. 7, 8 Not only is ZIKV detected in blood, it widely disseminates, with viral particles being detected in easily sampled compartments, such as urine, 9 semen, 10 and breast milk. 11 Understanding the rapid viral kinetics and widespread dissemination of ZIKV, including its apparent ability to cross both the blood-brain barrier 12, 13 and the placental barrier [14] [15] [16] will be vital in assessing and reducing infection risks, and to evaluate the effectiveness of therapeutic interventions.
Key questions in current Zika research involve the mechanisms of immune control of infection. Vaccines are in development, as reviewed in (17, 18) ; there is currently no safe and effective antiviral therapy and identifying and understanding key protective immune responses will be fundamental to both therapy and vaccine development.
Mathematical modeling has a long history of providing insight that would be difficult to obtain purely experimentally. Successes in modeling HIV and HCV infection and treatment [19] [20] [21] were followed by the development of models for acute viral infections such as influenza, [22] [23] [24] West Nile virus infection, 25, 26 dengue virus, 27, 28 Ebola virus, 29 and ZIKV. 30 Here, we review how mathematical modeling approaches can be applied to ZIKV infection.
| ZIK A VIR AL LOAD DYNAMI C S
Viral load is a key quantity used to assess disease burden and transmission risk and understanding the longitudinal changes in viral load during infection is the focus of most within-host mathematical modeling efforts.
In studies of patients presenting with symptoms of ZIKV infection, viral loads in serum have been measured ( Figure 1A) , showing variability in viral dynamics among patients. Different studies have found different distributions of the time to undetectable viremia. In a study of 15 infected males in Guadeloupe, 7 over 60% of patients had undetectable virus in serum by day 20 after symptom onset, while in another study involving 30 patients 31 the median time to clearance in plasma was estimated to be 11.5 days. A much larger study, 8 In one individual RNA was detected in semen as long as 9 months after symptom onset. 10 Given the association between ZIKV infection and birth defects, the course of infection in pregnant women has been of great interest, and sustained plasma viremia has been observed for >100 days. 32 Using data from people infected with ZIKV presents challenges for studying viral dynamics, since only data from patients who present at clinic is available, the date of infection is generally unknown, and only the viral dynamics after onset of symptoms are available for analysis. As such, animal models are used to obtain more controlled and detailed data. In mouse models, the innate immune response generally needs to be restricted in order to obtain productive infection 33 and thus this animal model is of limited use when investigating immune control of human disease. Many groups use non-human primate (NHP) models for studying viral infection, 34 and as reviewed by Osuna and Whitney 35 and Newman et al. 36 these provide a good model for human ZIKV infection, recapitulating many of the key clinical features including acute plasma viremia that is rapidly controlled, dissemination into multiple body compartments and, when infection occurs during pregnancy, fetal pathology and prolonged viral shedding. 37 In this review we will focus on mathematical modeling of NHP viral dynamics, as a technique to aid understanding of the pathogenesis of infection and evaluating potential therapeutic approaches.
Most NHP studies use a subcutaneous challenge model, intended to mimic infection via mosquito bite. Plasma viral dynamics after subcutaneous infection show acute infection dynamics much like those found in influenza, 22 characterized by a period of exponential growth that attains a peak viral load followed by a period of exponential decline until the virus becomes undetectable (Figure 2A and B). Subcutaneous infection with a low challenge dose ( Figure 2B) shows slower viral dynamics, with a later peak ( Figure 2C ) and generally delayed viral clearance ( Figure 2D ), as well as a lower peak viral load ( Figure 2E ) but a similar total viral burden ( Figure 2F ) as compared with a high-dose challenge ( Figure 2A ).
In addition to infection with different challenge doses, different viral strains have been used in different studies, which could well affect viral dynamics. Phenotypic differences have been observed
with different viral strains with Asian strains found to be less pathogenic, having a lower infection rate, less viral production, and poorer induction of early cell death than African strains. 38 Zika virus has been found to be able to infect a large variety of cells, including epidermal, placental, fetal, and neural cell types, [39] [40] [41] [42] [43] [44] [45] and in vivo infection studies in NHPs have found virus in many body compartments and tissues. 46 Virus has been found in semen after clearance in plasma, in agreement with human studies, thus allowing for further investigation into the risk of sexual transmission.
Zika virus infection of pregnant macaques ( Figure 3A ) results in prolonged maternal viremia as well as fetal pathology 37, 47, 48 and ZIKV infection of the fetus, 49 mimicking features of human infection. Similar results have also been found in marmosets. 50 These studies in primate models thus provide valuable data to aid understanding of the factors affecting fetal viral burden and the associated risk of severe fetal outcomes.
Plasma viral dynamics in NHPs infected via a mosquito vector ( Figure 3B ) were slower than in animals infected subcutaneously with 10 4 plaque-forming units (PFU) of ZIKV ( Figure 2B , blue triangles), however, the peak plasma viral loads were not statistically different. 51 The delayed peak viral load may be due to the fact that the effective challenge dose provided by the feeding mosquitos was lower than that given subcutaneously, as the amount of virus in the mosquito saliva was approximately 2-3 log 10 PFU. 51 This mosquito infection model is likely to provide essential information in comparing the highly controlled subcutaneous infection model to a more natural infection. The plasma viral dynamics following infection via mosquito demonstrates broadly similar behavior to those observed after subcutaneous infection, but with more variability between animals. A mathematical modeling approach might be able to quantify this variability. Additionally, other routes of infection have been studied in NHP models.
Saliva from infected animals, despite containing viral RNA, does not appear to be capable of transmitting infection. 52 To further understanding of sexual transmission of ZIKV, vaginal, and rectal challenges have been used, 53, 54 finding both routes are able to produce an infection measurable in serum ( Figure 3C ), with dynamics that look very comparable to the subcutaneous infection route.
| MODELING ACUTE VIR AL DYNAMIC S
The starting point for mathematical modeling of the within-host dynamics of most viral infections, including ZIKV, is usually plasma Figure 1 . Zika viral infection dynamics in human patients. Zika RNA concentration in (A) serum and (B) semen from patients presenting with acute infection, data taken from Joguet et al. 7 The dashed lines represent the reported experimental limit of detection of the assays. When samples contained undetectable ZIKV they are shown at the limit of detection
viral loads after infection, since these data are widely available, are broadly amenable to modeling, are often used in clinical assessment and may provide information regarding key aspects of the balance between viral replication and immune control.
The exponential increase, peak viral load, and exponential decrease characterizing acute plasma viremia could be described in a phenomenological manner via the rates and timings of the growth and decline phases, but in order to gain understanding of the underlying interactions between the virus and its host a model describing how these rates are produced is required. 25 and ZIKV. 30 Estimation of model parameters for a given set of viral dynamic data is the crucial first step to allow for insight into viral replication as well as enabling prediction of the efficacy of proposed therapeutic or vaccination strategies.
| Target cell-limited model
(1) The time to peak viral load, (D) the time to first undetectable viral load, (E) the peak observed viral load, and (F) the area under the curve (AUC) measured between log 10 viral load and log 10 assay detection limited, using a trapezoidal approximation. In (C) to (F), the marker color and shape is as for the data in (A) and (B) for high dose and low dose respectively, and p-values shown are from a Mann-Whitney U test
The viral load data obtained from NHP infection models ( Figure 2A and B) are amenable to individual model-fitting as well as population model-fitting approaches if data from enough animals are available.
With individual fitting, a parameter set is estimated for each subject separately, allowing for the best possible model fit for each animal.
Generally, the parameter set is selected to minimize the error between the model estimate and the observed data, on a log 10 scale. For most viral load measurements there is a known limit of detection of the RNA assay, and data points which fall below this limit of detection constitute censored data. The simplest way to include censored data in the fitting procedure is to assign an error of zero if both the observation and the model prediction are below the limit of detection, and to assign an error of the difference between prediction and limit of detection if the observation is below the limit of detection while the prediction is above. A more sophisticated treatment of censored data, as presented in (57) , presumes a distribution of data below the detection limit and integrates the error over this distribution.
A population fitting approach 58 allowing for analysis of, for instance, the predicted outcome of an antiviral therapy and the estimated number of animals that would be required in an experimental study in order to achieve enough statistical power to observe the effect of therapy.
| Basic reproductive ratio
An important concept in models of infection, whether at the epidemiological scale or the within-host scale, is the basic reproductive ratio, R 0 , which represents the number of secondary infections produced by one infectious unit (person, in an epidemiological setting, or cell in a within-host setting) being introduced into a wholly susceptible population. For the target cell-limited model (Equation 1), the reproductive ratio can be derived as R 0 = βpT 0 /(δc), 59 and in some modeling studies the choice is made to reparametrize the model, estimating R 0 rather than β (eg Snoeck et al. 60 ). We find this to be useful when estimating population distributions of parameters, allowing a description of the value of R 0 throughout the population rather than having to combine the estimated distributions of the other parameters in order to describe R 0 . We have also seen that estimating R 0 instead of β tends to provide a more stable fitting procedure, and sometimes provides a better model fit, 30 as assessed by log likelihood or the Bayesian information criterion. 61 There has been concern around the possibility of ZIKV transmission via blood transfusion, and estimation of the basic reproductive ratio in vivo is of much importance in understanding the amount of time between infection and detectable plasma viral load due to its effect on the rate of exponential viral growth. 59 A recent screening study of the U.S. blood supply 62 found there to be very low risk of transmission via blood transfusion, although this is likely to be increased in countries with a higher incidence of ZIKV infection.
| Parameter identifiability and constraints
Whichever fitting method is chosen, it is important to be aware of constraints around identifying all the model parameters. In this model, fitted solely to viral load data, the parameter p and the initial condition T (0) are only identifiable as the product pT(0). 63, 64 We generally choose to fix Haddow et al. 54 In all panels, the dashed line represents the reported experimental limit of detection of the assay. When samples contained undetectable ZIKV they are shown at the limit of detection
is between 500 and 1000, 65 giving a limitation that p/δ > (RNA/PFU)R 0 .
Additionally, care needs to be given to the practical identifiability of model parameters given the available data, as discussed for example by Miao et al., 63 Guedj et al. 66 and Nguyen et al. Furthermore, the expression for the basic reproductive ratio be-
, with the additional term describing the fraction of I 1 cells that survive the eclipse phase to become productively infected. 70 Incorporating a rate of cell death during the eclipse phase is supported in the case of HIV infection, where it is known that protein from infecting virus can be presented on MHC-1 molecules before the cell begins producing new virions. 71 Therefore, the immune system is able to recognize and attack HIV-infected cells while they are still in the eclipse phase. Whether this is a mechanism that also exists in ZIKV-infected cells is currently unknown, and if the length of the eclipse phase is fairly short it appears reasonable to ignore cell death during the eclipse phase.
The assumption of an exponentially distributed eclipse phase ( Figure 4A , black) does not need to be made for modeling purposes, nor is it an experimentally validated assumption: it is simply the most straightforward. Careful and detailed in vitro influenza 72 and SHIV 73 infection experiments provide support for non-exponentially distributed eclipse phases, finding that a gamma-distributed time to productive infection describes the observed data far more accurately than an exponential distribution. A gamma distribution with an integer shape parameter, an Erlang distribution, for the time spent in the eclipse phase can be easily described as a series of ODEs 74 :
where cells in compartments E 1 , …, E n are in the eclipse phase, and the sum of the exponential distributions (the time spent in each compartment E 1 to E n ) provides a gamma distribution with integer shape parameter n, an Erlang distribution ( Figure 4A , green). An Erlang distributed eclipse phase has been used in mathematical modeling studies of influenza [75] [76] [77] and HIV 74 infection, although it should be noted that use of the Erlang distribution introduces an additional parameter and therefore despite potentially describing the biological processes more realistically might not be justified by model selection criteria. As the integer shape parameter n tends to infinity, the distribution becomes tighter and tends toward a point distribution that is a fixed length eclipse phase ( Figure 4A , blue), exactly equal for all cells. A model wherein all cells spend a fixed amount of time τ (= 1/k) in the eclipse phase has been used for modeling HIV 78 as well as influenza 79 and can be described using delay differential equations:
where we set δ 1 = 0 if we assume there is no cell death during the eclipse phase. In this model with a fixed length eclipse phase the increase in I 2 due to infection events only depends on the concentration of target cells and of virus at time t − τ, meaning that the ODE for I 1 can be omitted 78 :
(2) 
| MODELING IMMUNE CONTROL OF VIREMIA
The 
| Innate responses in ZIKV infection
In ZIKV infection, both innate and adaptive responses have been shown to be important for viral control in various experimental models. In order to obtain productive infection in adult mice, type I interferon (IFN) responses generally need to be knocked out. 33 Similarly, wildtype neonatal mice who possess undeveloped immune systems are able to be infected, 80 with pathogenesis being both dose and age dependent. In humans, ZIKV is able to suppress the type I IFN response by targeting the transcriptional activator STAT2
for proteasomal degradation, but this does not occur in mice, which may explain the requirement of knocking out the IFN response in mice to generate productive infection. 81 ZIKV has also been shown to be able to avoid the host NK cell cytotoxic response by causing
upregulation of MHC class I molecules, an NK cell inhibitor, on the surface of infected cells in vitro. 
| Adaptive immune responses and antibodymediated protection
There has also been much effort directed toward understanding the generation and protective capacity of anti-ZIKV antibodies, as reviewed in Priyamvada et al. 83 In macaque models, after a high-dose intravenous infection, total numbers of B cells increased on day 3, while antigen-specific IgG titers were not detectable until well after clearance of the plasma virus, suggesting that the antibody response was more important for long-term protection than short-term control. 84 The long-term protective role of antibodies in ZIKV infection is supported by work from a number of groups. 85, 86 Aliota et al. 85 found that rhesus macaques were protected from secondary homologous and heterologous challenge 70 days after primary infection. Secondary challenge produced no detectable virus in plasma, urine, and semen, although neutralizing antibodies were increased after secondary challenge, suggesting that some low-level viral replication occurred but that the animals were protected from disease.
Similarly Osuna et al. 86 saw protection from secondary heterologous challenge 45 days after primary infection. A secondary heterologous challenge of a marmoset 87 12 months after primary challenge also produced no detectable viremia but increased antibody titers were observed, demonstrating the ability of ZIKV antibody protection to persist longer term.
In humans, virus-specific antibodies are seen to develop as early as 3 days after the onset of fever, 88 although in some studies IgM was not detectable until 8 days after symptom onset 9 with IgG developing even later in flavivirus-naive patients. 31 Cross-reactivity between ZIKV and antibodies to dengue virus 89 has been observed, complicating both ZIKV diagnosis and assessment of vaccineinduced immunity. 90 This cross-reactivity means that concerns around antibody-dependent enhancement (ADE) leading to severe disease on repeated dengue infections 91 are also present with Zika infection, and in vitro studies have demonstrated the ability of dengue antibodies to drive Zika ADE. 92 However, in NHP infection models, no evidence has been found for prior flavivirus infection worsening ZIKV infection 93, 94 and there is some suggestion that prior dengue exposure may even be beneficial in Zika infection, since a cross-reactive dengue antibody has been shown to be protective against ZIKV infection in mice. 95 T-cell responses have also been shown to be capable of providing protection against ZIKV infection. In immunocompetent mice infected with ZIKV, a T cell response is seen by 7 days postinfection, with antigen-specific IFNγ-producing CD8 T cells generated. 96 These CD8 T cells, on transfer to IFNα receptor knockout mice, protect from weight loss and reduce ZIKV burden after infection.
Additionally, depletion of CD8 T cells results in higher viremia in mice. 97 However, despite this evidence of T-cell response to ZIKV infection in mice, in rhesus macaques populations of CD8+ T cell subsets remain mostly stable during the course of infection. 84 In the situation where the immune responses that should be incorporated into models are broadly unknown, each potential response can be modeled and tested via data-fitting in order to suggest areas for further experimental focus. There are a number of feasible mechanisms of immune control of viremia, each of which can be implemented in the ODE models described by Equations (1)- (6) as we discuss below.
| Innate immune response models
It is known that for some viruses host type I IFN production, in response to viral infection, is able to put some cells into a protected or "antiviral" state 98, 99 and thus reduce their susceptibility to infection.
Type I IFN can also reduce the rate of viral production from infected cells as has been shown in the case of HCV. 20 This innate immune response can be modeled via an additional ODE describing the production of IFN from productively infected cells, at some rate and usually after some delay 22 :
where X denotes the concentration of IFN present, s is the IFN production rate per infected cell which can be set to 1 without loss of generality (although this results in X being measured in arbitrary units), τ is the length of the time it takes for IFN to be produced and able to act, and α is the rate of IFN degradation and loss due to cell uptake. replaced by ϕXT/(X+ϴ) where ϴ is a constant could also be used (V.
Madelain and J. Guedj, private communication). In this formulation,
ϕ is then the maximum rate at which a cell can become protected.
If the effect of the IFN response is modeled as a reduction in the viral infectivity, the ODEs for the target cell and eclipse phase populations become
where γ is a parameter describing the strength of the immune effect.
With this model the plasma viremia is reduced without the "loss" of target cells ( The examples of the dynamics from each of these models ( Figure 5 ), all demonstrate the same pattern: an innate immune response is able to control plasma viremia more rapidly than the target cell limited model, but also allows for viral recrudescence after the immune response wanes due to viral load reduction. Since any of these immune responses reduces viral load, fewer target cells become infected. Therefore, when the immune response wanes, due to lack of infected cells to produce IFN or to activate NK cells, a large proportion of the initial susceptible target cells are available to be infected by the small amount of virus that remains in the system and viremia can grow, until it is again controlled by the immune response.
We do not see this viral recrudescence in the viral loads from acute infections in NHPs. Using an ODE model structure in which variables are real numbers rather than integers there is no possibility of complete extinction of the virus, while in reality at low copy numbers there is a probability that the last infected cell dies and the last virus particle is cleared before infecting a new target cell so that the viral infection is eradicated. One can artificially where X is interpreted as the antibody concentration. 114 Which of these models of immune control of viremia is most appropriate to apply to ZIKV is not obvious. In Osuna et al. 86 a wide range of immune cell subsets and cytokines were measured during acute ZIKV infection. In order to determine which may be important for viral control, and therefore which should be included in models, we performed a number of correlation analyses looking to see if an increase in any immune parameter correlated with a decrease in virus. 30 After correcting for multiple testing, none of our analyses revealed a strong signal of a mechanism of immune control. We also saw that the dynamics of the changes in IFN concentration and levels of NK cells and CD8 effector effects observed after ZIKV infection, and shown in Figure 6 , were not readily described by any of the generally used models of immune response discussed above (Equations 11, 16, 17) and illustrated in Figure 5C . In particular, the IFNα response showed an early peak in most, but not all, animals, but this waned in many animals before the plasma viremia was controlled, and continued to increase in some animals after plasma viral load became undetectable. 30 Due to this, we were not able to use a viral dynamics model incorporating a simple model of immune response to fit these data. 30 Interestingly, we also observed that the immune dynamics were much more varied between animals than the plasma viral dynamics. This high level of heterogeneity in immune dynamics resulting in little heterogeneity in viral dynamics perhaps Thus, using measured immune data such as shown in Figure 6 we were still unable to find statistical support for any viral dynamics model incorporating immune control in fitting the viral load data presented in (30, 86) . This is possibly attributable to the high viral challenge dose of 10 6 PFU and the subsequent rapid viral dynamics seen in this study.
The question of the appropriate challenge dose to use in animal models, in order to most accurately model the dynamics of natural infection or to extract most information regarding the immune response, is still open. The saliva of infected mosquitos has been found to contain 2-3 log 10 PFU of ZIKV, 51 or on average 5-6 log 10 RNA copies. 115 Low subcutaneous inoculum doses are associated with delayed and prolonged viremia 116 but no substantial host gene transcriptomic clustering by dose was observed over a 3 log 10 dose range. A full analysis of the limited data available on the effects of inoculum dose on ZIKV viral load has not yet been published, but analyses of data from adenovirus infection of cotton rats and infectious bronchitis virus infection of chickens found a correlation between inoculum dose and both time to peak viral load and duration of infection. 117 Furthermore, this study found that mathematical models incorporating both innate and adaptive immune responses were required to recapitulate all the observed dose-dependent relationships. 117 New ZIKV studies exploring dose-dependent relationships might thus provide insights into the type of immune responses that control plasma viral load.
| MODELING ANTIVIR AL DRUG TRE ATMENT
Mathematical modeling of viral dynamics allows for exploration of various therapeutic options and has provided insight into antiviral efficacy in HIV and HCV. 103, 118 The effect of an antiviral drug can be modeled by modulating the appropriate rate parameter with a term If there is no detailed information about the efficacy of potential antiviral therapies, modeling can predict the efficacy required in order to restrict viremia by a particular amount. In particular, the reproductive ratio under any of these 3 antiviral drug models becomes R 0 = (1 − )R 0 , and as such the drug efficacy required to reduce this to below 1 and therefore prevent viral infection taking hold is
, where ε c is called the critical efficacy. 121 Much effort has been applied to discovering antiviral drugs active against ZIKV. 122, 123 One promising candidate, BCX4430 now called galidesivir, has shown potent activity in ZIKV-infected NHPs. 124 For many potential drugs the EC 50 , that is, the concentration required to provide 50% inhibition of viral replication, has been measured in vitro. For a given drug concentration C, the drug efficacy could be assumed to be ε = C/(C+EC 50 ), or more generally by an expression including a Hill coefficient n, 125 ε = C n /(C n + EC 50 n ). Using either of these equations, the effect of different constant drug concentrations on the viral load dynamics can be assessed. Applying this approach to ZIKV, 30 we found that for a drug reducing the viral production rate with efficacy ε = C/(C+EC 50 ) under the target cell limited model with an exponentially distributed eclipse phase (Equation 2), the time to undetectable viral load and the total viral burden is increased at low C/EC 50 ratios and only when this ratio exceeds a particular threshold is there improvement in these two measures above the case in which no drug is applied ( Figure 7 ). The concentration threshold above which drug reduces viral burden depends on the viral dynamics parameters. This increased viral burden at low drug concentrations is due to the slower infection of target cells, which prolongs the viral infection ( Figure 7A ). While this result is worrisome, it may not be realistic in circumstances where an immune response develops and controls viremia, or for effective drugs where concentrations well above these thresholds are attained. Also, presuming a constant drug concentration applied from the time of infection is not realistic in any clinical setting. A more comprehensive approach to modeling the effect of an antiviral drug is to adopt a time-varying drug concentration, which then leads to a model incorporating both pharmacokinetics and pharmacodynamics, as has been done for the treatment of other viral infections. 29, 126, 127 Analysis of ZIKV dynamics during antiviral therapy can provide insight into therapy efficacy, but could also provide further evidence regarding immune control. If target cell limitation is the key component of immune control, we might expect a delay in viremia but not reduction in total viral shedding on antiviral therapy. However, if antiviral therapy is seen to both delay and reduce viremia then this suggests an immune response is key to controlling viremia and as such a model incorporating an immune mechanism, as described early, would be required to fully describe the observed data. 
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